Hereditary Cancer Genetic Testing
How might hereditary cancer genetic testing help me and my family?
Depending on the gene, testing positive for a pathogenic variant could mean that you have an increased risk of developing certain types of cancers. Because pathogenic variants often run in families, your relatives may also have inherited the same variant. Genetic testing can help you and your family members:
- Understand the types of cancer(s) you may be at increased risk to develop
- Develop appropriate screening strategies with your healthcare provider to prevent cancer or identify it at an earlier stage
- Determine the best treatment approach if cancer occurs
I have cancer (or had cancer before). Should I still be tested?
You can still benefit from hereditary cancer genetic testing even if you currently have cancer or have been diagnosed with cancer in the past. Genetic testing can help identify if there is an underlying hereditary cause for your cancer. This test might help you and your healthcare provider:
- Better understand your risk of developing additional cancer(s)
- Identify strategies to reduce the risk of developing additional cancer(s)
- Determine the best treatment approach for certain types of cancers
- Help to identify family members who may be at increased risk – learn more
Family History Questionnaire
Designed to help you assess your risk of hereditary cancer. Should only take a few minutes to complete.
Pre-test educational video
If your doctor determines that a hereditary cancer test is right for you, they may ask you to watch this informational video to learn more about the testing process.
1. ACOG Hereditary Cancer Syndromes and Risk Assessment. ACOG COMMITTEE OPINION SUMMARY, Number 793. Obstetrics & Gynecology: December 2019 – Volume 134 – Issue 6 – p 1366-1367.; 2. The National Cancer Institute: The Genetics of Cancer. August 17, 2022.; 3. Lindsay Dohany, et al. Hereditary cancer risk assessment using a chatbot in women presenting to obstetrics and gynecology practices across the U.S. [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-08-39.; 4. Frezzo, T., et al. The genetic family history as a risk assessment tool in internal medicine. Genet Med 5, 84–91 (2003).; 5. DeFrancesco MS, et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstet Gynecol. 2018 Nov;132(5):1121-1129.; 6. Buys SS, Sandbach JF, Gammon A, Patel G, Kidd J, Brown KL, Sharma L, Saam J, Lancaster J, Daly MB. A study of over 35,000 women with breast cancer tested with a 25 gene panel of hereditary cancer genes. Cancer. 2017 May 15;123(10):1721-1730.; 7. Walsh T., Casadei S., Lee M. K., et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(44):18032–18037.; 8. Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer 2005;104:2807–16.